|
Oct 7
|
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit
|
|
Sep 24
|
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting
|
|
Aug 7
|
BrainStorm Cell Therapeutics to Announce Second Quarter Results and Provide a Corporate Update
|
|
Jul 24
|
BCLI Update - Progress Supports Our 10x Plus Value Range Potential
|
|
Jun 27
|
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
|
|
Jun 26
|
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
|
|
Jun 14
|
BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation
|
|
May 14
|
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Apr 16
|
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
|
|
Apr 11
|
BCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™…
|
|
Apr 11
|
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
|
|
Apr 10
|
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
|
|
Apr 9
|
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
|
|
Apr 8
|
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
|
|
Apr 1
|
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
|
|
Mar 6
|
BCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS…
|
|
Dec 20
|
BrainStorm Issues 2023 Letter to Shareholders
|
|
Dec 8
|
BCLI: FDA Meeting Provides Clear Path for Planned Phase 3b Trial of NurOwn
|
|
Dec 7
|
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS
|
|
Apr 24
|
BrainStorm Cell Therapeutics Strengthens Leadership Team with Appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer
|